diseases 17 , although the mechanistic basis for their involvement remains unknown in many cases and new therapies based on these linkages often remain a distant prospect.
What is needed
However, science cannot rest on those laurels. A dispassionate view of the larger landscape of human disease and the functioning (or malfunctioning) of the immune system makes it all too clear that knowledge is limited and the ability to identify the right targets and produce therapeutics with higher efficiency and selectivity is still inadequate. Many critical vaccines are lacking because the best way to elicit the desired immune response to the relevant infectious agents or even if the immune system is capable of the required protective response-qualitatively or quantitativelyremains unknown [18] [19] [20] [21] [22] [23] . It is unclear what initiates many of the chronic inflammatory conditions that contribute to malignant transformation and cancer progression, to aberrant metabolism or to inflammatory bowel disease. Only an early glimpse exists of the connection between the microbiota on the skin and mucous membranes or in the gut and a person's overall health, immune status and response to environmental perturbations in the context of diverse genetic backgrounds 24, 25 . In some cases there is reasonable knowledge about relevant participants in a disease state but not about how these components are connected. Moreover, quantitative understanding is lacking about how much one or another molecule or cell population needs to be neutralized or eliminated to produce the desired therapeutic effect without posing an unacceptable risk of sity 4, 5 , chronic obstructive pulmonary disease 6 , atherosclerosis 7 and many others?
Present state of the art
The good news is that tremendous progress has been made in the past few decades in translating basic findings about the immune system from both animal models and human studies into new therapies that have had a substantial effect on human health. In some cases, the tools are blunter than is desirable but nonetheless are quite effective 8, 9 . These include a raft of immunosuppressive drugs such as cyclosporin or rapamycin that permit tissue transplantation and ameliorate several autoimmune diseases. In other cases, specific molecules involved in driving devastating symptoms, if not themselves responsible for the underlying inciting events, have been identified for several syndromes. Spectacular patient improvement is seen with specific biological therapies, mainly monoclonal antibodies or soluble receptor analogs 8, 9 , that neutralize the offending substance, whether interleukin 1b (IL-1b) in several autoinflammatory syndromes 10 , tumor necrosis factor in rheumatoid arthritis 11 and psoriasis 12 , or IL-6 in juvenile arthritis 13 . In some cases, these approaches represent some of the most dramatic examples of successful therapy for patients with defined monoallelic genetic disorders 10 . The use of IL-1Ra for gout and pseudogout [14] [15] [16] provides an excellent example of well-designed therapeutics and rational drug design based on the biology of the disease. An explosion in genome-wide association studies has led to the identification of key genetic loci at which allelic variation is linked to a variety of immune and autoimmune I n medical school, physicians are taught the four classic signs of inflammation-rubor, dolor, calor and tumor (redness, pain, heat and swelling)-a tetrad first recorded by Celsus in the first century ad 1 . Much progress has been made since then, and these signs can be explained on the basis of the functions of specific cells, molecular mediators and tissue responses. Indeed, the wealth of information about even a simple inflammatory response can be overwhelming when brought together in one place, as in any of the attractive diagrams put out by various journals or drug companies for the edification of clinicians and researchers. But 32, 44 . The result is a segue from small-scale, descriptive science to more global insights into how the complex machinery of the immune system is wired together and what happens to the activity of these highly connected circuits when one or another part is missing, hypoactive or excessive in its function. The effects of drug interventions can be simulated through the use of such network models, whether built at the molecular, cellular, tissue or organ level 49, 50 . New algorithms for diagnosis, patient stratification and targeted therapeutic intervention can be derived from such analyses. The cancer literature now provides a wealth of examples of the use of such personalized analyses to guide therapeutics 51, 52 , and the application of such techniques to immune system-mediated disease is clearly a high priority 35 .
Impediments to implementation
Just because new machines and methods are available, however, does not mean they are being or will be effectively used, that additional technologies are not urgently needed, that the social fabric of the research enterprise is optimally suited to take advantage of these opportunities, or that the support for research will be adequate to make progress as rapid as might otherwise be. Each of these issues poses a substantial obstacle to the acquisition of insight into the function of the human immune system of the microbiome 38 so this important factor in setting the 'tone' of the immune system 39, 40 can be factored into analyses along with measurements of the host's condition. Such advances also suggest that insight may be provided into environmental influences long known to contribute to immunological disorders, such as multiple sclerosis 41 .
There have also been major improvements in single-cell analytical technologies, chief among these being fluorescence-based flow cytometry. This methodology now allows nearly routine analysis of nine to ten parameters, or of as many as fifteen with some difficulty, permitting detailed profiling of cellular subsets in blood and other samples 42 (although more automated analytic tools are needed to handle these dense data sets). However, even those numbers may soon be grossly exceeded by the application of mass spectrometry to cellular phenotyping 43, 44 ; indeed, Stanford scientists are now measuring as many as 37 parameters per cell, combining surface-maker analysis with 'multiplexed' staining for intracellular cytokines and phosphorylated proteins, not only to define the type of cell being examined but also to learn about its state of functional activity 45 . The technology of mass spectrometry is also advancing rapidly, allowing much deeper quantitative analysis of the protein, lipid and metabolic components of cells, serum and other bodily fluids of interest [46] [47] [48] .
The second thread is the development of new statistical and computational methods for the analysis of enormous data sets, which opportunistic infection or the recrudescence of one of the many 'endogenous' infectious agents typically kept in check by an intact immune system. The last is a major problem for the use of drugs directed against tumor necrosis factor because of the emergence of M. tuberculosis from latency 11, 26 , and it temporarily halted the use of natalizumab, an antibody that blocks the integrin a 4 , because interference with effector function in the central nervous system allowed reactivation of latent virus and the development of progressive multifocal leuokoencephalopathy 27 .
A path forward The summary above might elicit despair about the possibility of rapid progress in solving the many outstanding and complex issues. However, the emergence of new tools and technologies and concerted efforts to apply them give hope that the future can be very bright. It is increasingly apparent that the pace of not just information acquisition but also the development of a deep understanding of human immunophysiology and immunopathology is accelerating. Two interwoven threads are responsible for this positive outlook.
The first theme is the emergence of methods and instruments that permit global or near-global analysis of gene expression, genotype, epigenome, cell surface and functional phenotype, serum protein composition and so on-that is, methods and instruments that measure in much greater depth and breadth the composition and state of the immune system than did previous limited tests of serological or cell-mediated immunity 23, 28, 29 . Cost-effective ways are available to analyze a person's genetic makeup 30 and also to probe genome-wide transcriptional states with commoditized microarrays and, soon, by second-and thirdgeneration sequencing methods 31 . This enables investigators to conduct broad and deep analyses of gene expression by hematopoietic cells of the immune system, obtained mainly but not exclusively from peripheral blood and, increasingly, from small tissue samples that can be collected ethically and then to relate these findings to a person's history and genotype. The power of such a genomic approach is evident in some of the remarkable insights and drug leads that have arisen from studies of expression-quantitative trait loci and Bayesian inferential modeling of various diseases such as obesity and diabetes 32 , as well as in the effective use of expression profiling in facilitating the diagnosis and prognosis of patients with various infectious 33, 34 and autoimmune diseases 35 or in the development of predictors of vaccine efficacy 36, 37 Figure 1 The intertwined cycles involving hypothesis-driven research and systems-level analysis. Each of the three funnels represents a major collaborative group that conducts clinical and '-omic-scale' data collection and computational analysis; these groups also provide data for meta-analyses. The interpretation of the data from such hypothesis-generating activities is based on knowledge acquired by hypothesis-driven research; the data and findings from the systems analyses help drive further directed research at a fundamental level.
c o m m E n Ta r y
Diseases of the National Institutes of Health) is discussing how to ensure that data compatibility and aggregation of the large-scale, immune system screening efforts these groups will be undertaken in the coming years (http://www. niaid.nih.gov/news/newsreleases/2009/pages/ hipro.aspx). The intramural Center for Human Immunology, Autoimmunity and Inflammation of the National Institutes of Health has made the creation of a well-curated public database of information arising from its studies of human immunity a top priority (http://www.nhlbi. nih.gov/resources/chi/). The Immunological Genome Project, although initially focused on transcriptional profiling of mouse cells, is moving to analysis of human hematopoietic cells (http://www.immgen.org/index_content. html) and puts its data online in a very rapid and easily accessible manner (including an iPhone application). Data storage, curation and accessibility are all critical issues that are not yet resolved for the more clinical of these studies. Will an early-release strategy similar to that of the Human Genome Project 55 be a viable way forward, so that the entire community can examine the data at the earliest time? How will the contributions of investigators be recognized in such a case? How can the data be made anonymous while still being connected to critical clinical and patient metadata? There is above all an urgent need to address the sociology of academic translational research: viable career paths must be defined for people who are members of these necessarily large teams whose main output will be publications with extensive coauthorship; in this context, the Intramural Research Program of the NIH has taken a first step by incorporating special tenure consideration for authors on such team-science publications (https://ccrod.cancer.gov/confluence/ display/NIHOMBUD/Evaluating+Contributio ns+to+Team+Science).
Finally, there is the issue of money. It can be argued cogently that success in exploring the function and dysfunction of the human immune system will lead to new methods for preventing and treating disease, with a concomitant decrease in overall healthcare costs in the long term. Nonetheless, there is clearly a short-term cost to be borne in applying these various (expensive) technologies and supporting the substantial professional staff necessary for their proper use and interpretation of the emerging data. Where will these funds come from? In many countries, especially those in the western hemisphere 58 , the recent financial meltdown has raised questions about whether substantial new money will be made available for research in the coming years. Will there be an intensification of the 'us-versus-them' debate about investigator-initiated grants verbe studied, and even for ways to probe tissues in situ in a noninvasive manner to complement ex vivo methods. In the near term, such an ability could be provided by the judicious application of advances in magnetic resonance imaging based on targeted contrast agents. Probes are being developed that each give a distinct signature, which allows 'multiplexing' as in flow cytometry, and that are self-amplifying and hence useful for the detection of weak signals without inordinately long imaging times 54 . These could allow noninvasive probing of cells and perhaps even of secreted factors located in tissue sites anywhere in the body where probe penetration is adequate, which is probably the case in inflammatory sites with vascular leakage. Further work is needed to bring these early technical developments to a useful state. The creative development of other techniques for in situ study would also be extremely valuable.
In the third example, scientists are faced with learning how to be more interactive. As in particle physics, in which small laboratory science gave way to large-scale team-based studies, or the Human Genome Project 55 and the Encyclopedia of DNA Elements Pilot Project 56 , which have relied on large multidisciplinary teams in well-equipped and well-funded centers, multiplex, large-scale studies of the function of the human immune system will require a combination of expertise and facilities beyond those available in a typical laboratory directed by a principal investigator 23, 29, 49 . In addition, to aggregate enough information about normal people and especially about patients with a specific disease, it will be necessary to combine data from multiple centers. The importance of such cooperative studies (Fig. 1) is evident in recent genome-wide association studies, such as those examining diabetes or autoimmunity, in which a single well-powered study has been published by a consortium of centers in each case, rather than being submitted as many smaller, underpowered reports from individual laboratories 17, 57 . This lesson on pooling resources has not been lost on those studying human immunity. For example, the Cancer Immunotherapy Consortium of the Cancer Research Institute has proposed an ImmunoAssay Proficiency Panel Program to allow data from diverse studies to be 'harmonized' and included in meta-analyses (http://www.cancerresearch.org/consortium/ assay-panels/). This is also a recommendation of the Global HIV Vaccine Enterprise for future studies of the function of the immune system in people infected with human immunodeficiency virus and vaccines against this virus (http://www.hivvaccineenterprise. org/scientific-strategic-plan). The Human Immune Project Consortium (funded by the National Institute of Allergy and Infectious needed to diminish the burden of disease and, hopefully, the associated costs.
In the first example, many investigators trained in traditional methods of inquiry are hesitant to adopt very different ways of conducting science. Technologies, bioinformatics and computational systems biology on the '-omic' scale together allow an agnostic approach to a question in which newly generated data guide future experimental work. This contrasts with the more classic approach of beginning with a clear hypothesis based on past knowledge that limits the scope of inquiry, which in turn may lead the investigator to miss consideration of relevant elements that had not been previously suspected in this context and thus are not examined. There is no question that research using biological knowledge and insight to guide focused, selective experimentation will not lose its great value and will continue to provide critical new 'aha' moments. Indeed, such focused work led to the discoveries needed for the '-omic' and network approaches now considered so central to future progress. Furthermore, such guided research is critical for the evaluation and translation of findings from large-scale '-omics' studies (see Fig. 1 ). However, it would be a mistake to underestimate the potential of the recently acquired ability to probe a system both broadly and deeply without preconceived ideas of how it operates and discover entirely new mechanisms underlying physiological or pathological activity. One striking example involves recent studies of metabolic syndrome using analysis of expression-quantitative trait loci with transcriptional profiling tools. Although they confirmed a major genetic and transcriptional signature involving pathways of intermediary metabolism, what also emerged was an unexpected macrophage-centered signature 53 . Such examples suggest that these approaches will be informative for understanding the underlying pathology in other diseases in which contributions of the immune system may not normally be considered key elements. In turn, such findings will continue to fuel hypothesis-driven, focused experimental science that propel research to the next phase of translating them to achieve better understanding and treatment of human disease (Fig. 1) .
In the second example, the present methods are reasonably well developed for analysis of cells in the blood and, to a more limited extent, biopsy specimens of a reasonable size. This limits which tissue and organs can be examined robustly, especially in normal people, yet normal data are needed as a baseline for understanding the perturbations present in disease. There is an urgent need for the miniaturization of methods so that fewer cells or smaller tissue samples can c o m m E n Ta r y long-term value in both types of work and do not starve these efforts in their infancy.
sus large program support that has simmered for years 59 ? Or will the rapid deposition in public repositories of the data emerging from the large-scale studies, data that can then be mined by everyone, along with the recognition that science funded by R01 grants is a critical complement to these large-scale studies, assuage some of these concerns? Will public servants (that is, legislators) take the longer term view that rapid acquisition of the knowledge and insight promised by these new approaches will ameliorate rapidly rising healthcare costs and that, even in times of budgetary limitations, it is a good investment to avoid cutting and possibly even add to the allocation for biomedical research? Will the biotechnology and pharmaceutical industry consider these large efforts as generating data they consider 'pre-competitive' and form a consortium to help underwrite the cost of developing this globally valuable information? Will that industry contribute in another manner, through low-cost or no-cost provision of drugs for studies of the effect of therapy on the immune system, not only when it represents the intended aim but also when it may be considered an 'off-target' effect (such as for many drugs used in cancer therapy)?
Concluding remarks
Each year, the President of the United States goes before Congress to describe the state of the union, and nearly every year, the speech begins with "The State of the Union is good. " In considering the state of modern human immunology, it is believed accurate to conclude that the situation is also good, perhaps even excellent. The field has an exciting future if the recent nascent efforts to power up global assessments of the human immune system do not falter; if those involved in such studies keep their eye on the goal of real progress in disease prevention and therapy; if there is effective cooperation between those conducting more traditional hypothesis-driven research efforts and those involved in studies on a larger scale, with their focus on team science, global data gathering and computational analysis; and if the larger public and its representatives see the
